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Background: Multiple infection outbreaks have been linked to contaminated duodenoscopes worldwide.
However, the contamination rate of patient-ready duodenoscopes varies highly amongst published studies
testing this subject. We aimed to estimate the contamination rate of reprocessed patient-ready duodeno-
scopes for endoscopic retrograde cholangio-pancreatography (ERCP) based on currently available data.
Methods: We searched the PubMed and Embase databases from January 1, 2010 until March 10, 2020, for
citations investigating contamination rates of reprocessed patient-ready duodenoscopes. Studies not assess-
ing other types of endoscopes than duodenoscopes were excluded from the analysis. Study eligibility and
data extraction was evaluated by three reviewers independently. A random-effects model (REM) based on
the proportion distribution was used to calculate the pooled total contamination rate of reprocessed patient-
ready duodenoscopes. Subgroup analyses were carried out to assess contamination rates when using differ-
ent reprocessing methods by comparing single high-level disinfection (HLD) with double HLD and ethylene
oxide (EtO) gas sterilization. Additionally, we investigated the contamination rate between studies con-
ducted following an outbreak compared to non-outbreak-initiated studies.
Findings: We identified 15 studies that fulfilled the inclusion, which included 925 contaminated duodeno-
scopes from 13,112 samples. The calculated total weighted contamination rate was 15.25% § 0.018 (95% con-
fidence interval [Cl]: 11.74% - 18.75%). The contamination rate after only using HLD was 16.14% § 0.019 (95%
Cl: 12.43% - 19.85%) and after using either dHLD or EtO the contamination rate decreased to 9.20% § 0.025
(95% Cl: 4.30% - 14.10%). Studies conducted following an outbreak (n=4) showed a 5.72% § 0.034 (95% Cl:
0.00% - 12.43%) contamination rate, and non-outbreak-initiated studies (n=11) revealed a contamination rate
of 21.50% § 0.031 (95% Cl: 15.35% - 27.64%).
Interpretation: This is the first meta-analysis to estimate the contamination rate of patient-ready duodeno-
scopes used for ERCP. Based on the available literature, our analysis demonstrates that there is a 15.25% con-
tamination rate of reprocessed patient-ready duodenoscopes. Additionally, the analysis indicates that dHLD
and EtO reprocessing methods are superior to single HLD but still not efficient in regards to cleaning the duo-
denoscopes properly. Furthermore, studies conducted following an outbreak did not entail a higher contami-
nation rate compared to non-outbreak-initiated studies.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
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Research in context
Evidence before this study
Worldwide, multiple outbreaks have been reported due to con-
taminated patient-ready duodenoscopes. In the past years con-
taminated endoscopes have gained more and more attention,
and The Food and Drug Administration (FDA) has recently they
stated that healthcare facilities should consider transition to
duodenoscopes with newer and innovative designs in order to
minimize the risk of infection. Despite multiple outbreaks, vari-
ous updated reprocessing guidelines, and safety communica-
tions, evidence is still missing within this topic. We aimed to
estimate the contamination rate of reprocessed patient-ready
duodenoscopes based on currently available data.
Added value of this study
Currently, no data exists on one generalizable contamination
rate of duodenoscopes summarizing all published evidence.
This study demonstrates a higher-than-expected contamina-
tion rate of patient-ready duodenoscopes. Current evidence is
limited, but with the increased focus on cross-contamination
an updated reference point is highly needed. Various studies
and guidelines are currently citating a study from the 1990s
stating that the risk of infection due to a contaminated duode-
noscope is 1 out of 1.8 million. However, new evidence suggests
that the risk is much higher which is also being support by the
interim results from the FDA postmarket surveillance study
showing a 9% contamination rate associated with reprocessed
duodenoscopes.
Implications of all the available evidence
Our study suggests that patient-ready duodenoscopes are asso-
ciated with a 15.25% contamination rate. Additionally, our
study indicates that none of the current reprocessing methods
are efficient in regards to cleaning duodenoscopes properly.
The findings highlight the need for more studies to be con-
ducted in the future to address issues related to contaminated
reusable duodenoscopes that may potentially lead to cross-
infections and patient harm following endoscopy.
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More than 600,000 endoscopic retrograde cholangio-pancreatog-
raphy (ERCP) procedures are performed annually in the United States
[1]. An ERCP procedure is an important and less invasive treatment
alternative to open surgery in the bile duct and pancreatic duct [2,3].
At present, these highly beneficial ERCP procedures are primarily per-
formed using reusable duodenoscopes; however, due to their com-
plex design, duodenoscopes are difficult to clean properly [46].
Insufficient cleaning of duodenoscopes results in microbiological
debris in patient-ready duodenoscopes, thus leading to patient-to-
patient cross-contamination, the transfer of multi-drug-resistant
(MDR) organisms, and subsequent infections [6,7]. Hence, contami-
nated duodenoscopes have resulted in multiple outbreaks and deaths
involving MDR organisms across the world [8,9].
Awareness of the risk of post-endoscopic infections caused by
contaminated duodenoscopes has increased significantly over the
recent years. On the 19 February 2015, the Food & Drug Administra-
tion (FDA) published the first duodenoscope-related Safety Commu-
nication; this stated that the design of duodenoscopes may impede
effective cleaning, and therefore lead to the potential transmission of
microorganisms in the patient-ready high-level-disinfected (HLD)duodenoscopes used for ERCP. From 2015 to 2019, 17 out of 85 (20%)
of the FDA’s Medical Device Safety Communications have been
related to endoscopes, predominantly targeting contaminated reus-
able duodenoscopes [10].
In October 2015, the FDA ordered manufacturers of duodeno-
scopes sold in the United States (Fujifilm Medical Systems USA, Inc;
Olympus Medical Systems Corporation; Pentax of America) to con-
duct post-market surveillance studies to evaluate contamination
rates and to clarify how duodenoscopes are reprocessed in real-world
settings. The interim results from these post-market surveillance
studies were presented in March 2019 and indicated higher than
expected levels of contamination [11]. Prior to the post-market sur-
veillance studies, the FDA expected a contamination rate lower than
0.4% [12]. In the post-market surveillance study, 5.4% of samples that
were collected appropriately tested positive for organisms of high-
concern (e.g., E. coli and P. aeruginosa). In addition, 3.6% of the col-
lected samples tested positive for organisms that were of low to mod-
erate concern (>100 colony-forming units (CFUs)); this constituted
an overall contamination rate of 9% [12]. Controversies still remain
with regards to the impact of contaminated duodenoscopes, and
whether such equipment can cause post-endoscopic device-related
infections that could impair patient safety [13]. Additionally, while
previous studies have summarized research on duodenoscope con-
tamination, no studies have provided an estimate of the actual con-
tamination rate associated with patient-ready duodenoscopes.
Therefore, the aim of this systematic review was to estimate the con-
tamination rate of patient-ready duodenoscopes based on currently
available literature.
2. Methods
2.1. Study selection
We carried out a comprehensive and systematic literature search
to identify full-text human studies, published in English, investigat-
ing contamination rates associated with duodenoscopes. The com-
plete literature search is presented in Figure 1. Methods of analysis,
and inclusion criteria, were based on the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) Guideline [14].
Studies were identified through a systematic literature search
from January 1, 2010 until March 10, 2020 in the PubMed and
Embase electronic databases. To identify and include relevant studies,
we conducted the search using the following medical subject head-
ings (MeSH) and keywords: (“duodenoscop*” [All Fields] OR “gastro-
intestinal endoscop*” [All Fields]) AND ((“infection*” [MeSH Terms]
OR “cross infection*” [MeSH Terms] OR “outbreak*” [All Fields] OR
“device contamination*” [All Fields] OR “hospital infection*” [All
Fields] OR “disinfection*” [MeSH Terms] OR “bacteria*” [MeSH
Terms]) AND English [lang]. Truncation was deployed after some key-
words to include different variations of the term.
2.2. Inclusion and exclusion criteria
The search was conducted to identify all relevant randomized
controlled trials, systematic reviews, meta-analyses, case reports,
surveillance studies, and prospective or retrospective cohort studies
assessing the contamination rate associated with reprocessed duode-
noscopes. The search was limited to studies published after 2010
since a time horizon of 10 years was considered reasonable due to
various updated endoscope reprocessing guidelines [1518]. For
inclusion, studies needed to state the total number of duodenoscopes
sampled (N) and the number of contaminated duodenoscopes (posi-
tive cultures). There was also the requirement that all samples were
acquired from a duodenoscope and not from a patient. Studies per-
formed in animals or in vitro models were excluded. Other exclusion
criteria were abstracts, editorials, and letters that did not report
Fig. 1. Flowchart describing the study process and the selection of publications.
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well. Lastly, studies with less than 10 samples were excluded to avoid
bias in the random effects model that may have arisen due to small
sample sizes [19].
The titles and abstracts of the identified studies were indepen-
dently reviewed by two authors (SL, HT). Studies that did not fulfill
the abovementioned criteria were excluded, and the full-texts of the
remaining publications were carefully independently evaluated by
three authors (SL, HT, RR). Disagreements were resolved by consen-
sus assessment.
2.3. Data extraction
All included studies were assessed for eligibility by three indepen-
dent reviewers (SL, HT, RR). None of the authors was blinded to any
information within the studies. For each included study, we extracted
the following data: author, year of publication, study design, country,
hospital, number of annual ERCPs, type of microorganism, number of
contaminated duodenoscopes (e.g., the number of positive samples),
total number of sampled duodenoscopes, reprocessing method, col-
ony forming unit (CFU) level, and sampling setting (e.g., outbreak vs.
non-outbreak).
2.4. Outcomes
The primary outcome of the pooled analysis was the total
weighted contamination rate based on the number of contaminated
duodenoscopes (the number of positive samples) relative to the num-
ber of duodenoscopes sampled. A subgroup analysis was carried outto assess the contamination rate amongst duodenoscopes reproc-
essed using HLD and duodenoscopes reprocessed with either double
HLD (dHLD) or ethylene oxide (EtO) gas sterilization to see if there
were any significant differences between the cleaning methods.
Another subgroup analysis was carried out to assess whether studies
conducted following an outbreak entailed a higher contamination
rate compared to non-outbreak initiated studies.
Patient-specific data were not assessed since the analysis only
focus on the duodenoscopes. There were no missing data for any of
the data points used to calculate the weighted contamination rate.
2.5. Data analysis and statistical methods
The meta-analysis analyzed data from studies where a duodeno-
scope contamination rate was assessed. The primary objective of the
analysis was to assess the total contamination rate of reprocessed
patient-ready duodenoscopes. Two subgroup analyses were carried
out to 1) assess the contamination rate of patient-ready duodeno-
scopes reprocessed using HLD and assess the contamination rate of
patient-ready duodenoscopes reprocessed using either dHLD or EtO
gas sterilization to compare the different reprocessing methods, and
2) assess the contamination rate for outbreak-initiated studies and
non-outbreak-initiated studies. For all statistical analyses we used
the meta package (metafor) in RStudio V.3.6.2. Data were pooled
using a random effects model based on proportions. We applied the
random effects model because we anticipated heterogeneity, particu-
larly arising from variations in both sample size and population. We
estimated the level of heterogeneity between the included studies
using the inconsistency index (I2) test, which indicates the proportion
Fig. 2. Pooled estimates of contamination rates. Cl: confidence interval.
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rather than being a coincidence [20,21]. Heterogeneity values below
25% were defined as being indicative of low levels of heterogeneity
[21]. Publication bias is known to impact the validity and generaliz-
ability of conclusions based on meta-analyses [22]. We assessed pub-
lication bias using funnel plots and evaluated the asymmetry of the
funnel using Egger’s regression test. A forest plot of all outcomes was
created using the random effects model, as shown in Fig. 2.
2.6. Role of the funding source
This study did not receive any funding.
3. Results
3.1. Characteristics of included studies
We identified a total of 2214 studies, of which 2107 of these stud-
ies were screened based on title and abstract review. After applying
our inclusion and exclusion criteria, the search was narrowed to 47
studies, which were reviewed in full detail. The PRISMA flowchart of
the literature search, and the selection process, is demonstrated in
Fig. 1. After assessing the full-text articles for eligibility, 15 studies
were included in the final analysis.
All of the 15 studies included in the final analysis were published
between January 1, 2010 and March 10, 2020. The included studies
yielded a sample size of 13,112 duodenoscopes that had been sam-
pled for culture testing. The total number of contaminated duodeno-
scopes (the positive samples) was 925.
The baseline characteristics of the included studies are provided
in Table 1. The majority of the included studies were conducted in
the United States (n=8, 53.3%), while the remaining 46.7% of the stud-
ies were conducted in the Netherlands (n=1, 6.7%), France (n=1, 6.7%),
Canada (n=1, 6.7%), Italy (n=1, 6.7%), Iran (n=1, 6.7%), and in Austria
(n=1, 6.7%). Twelve out of 15 (80.0%) studies report using HLD as the
reprocessing method, one study report using EtO (6.7%), and two
studies have tested a combination of both HLD, dHLD, and EtO
(13.3%). Six out of 15 (40%) studies report the CFU threshold used to
determine the contamination rate. Four studies (26.7%) are using the
recommended CFU threshold of >10 stated in the Center for Disease
Control and Prevention (CDC) protocol, while one study (6.7%) uses a
threshold of >20 CFU, and a study (6.7%) reports a CFU threshold of>100 CFU. Four out of 15 studies (26.7%) were conducted following
an outbreak, while the remaining 11 studies were conducted inde-
pendent of any outbreak detected.
3.2. Analysis of primary outcomes
Meta-analysis of the included studies demonstrated an overall
pooled contamination rate of 15.25% § 0.018 (95% confidence inter-
val [Cl]: 11.74% - 18.75%; I2 = 98.6%). Heterogeneity between the
included studies (n=15) was considered to be high. Funnel plot analy-
sis, and Egger’s regression test, for the included contamination stud-
ies indicated significant publication bias (Egger’s test of publication
bias: p<0.001) (Fig. 2). Funnel plots are presented in Supplementary
Figure 1.
3.3. Subgroup analyses
Meta-analysis of the included studies only assessing the contami-
nation rate after the duodenoscopes have been reprocessed using
HLD demonstrated a pooled contamination rate of 16.14% § 0.019
(95% Cl: 12.43% - 19.85%; I2 = 98.8%). Meta-analysis of the included
studies only assessing the contamination rate after the duodeno-
scopes have been reprocessed using either dHLD or EtO sterilization
demonstrated a pooled contamination rate of 9.20% § 0.025 (95% Cl:
4.30% - 14.10%; I2 = 92.3%). Heterogeneity between the included stud-
ies for both populations (HLD vs. dHLD/EtO) was considered to be
high. Meta-analysis of outbreak-initiated studies (n=4) demonstrated
a pooled contamination rate of 5.72% § 0.034 (95% Cl: 0.00% -
12.43%). Non-outbreak-initiated studies (n= 11) showed a contami-
nation rate of 21.50% § 0.031 (95% Cl: 15.35% - 27.64%). Heterogene-
ity in both populations was considered high.
4. Discussion
This study is the first to estimate the contamination rate of
patient-ready duodenoscopes used for ERCP based on currently avail-
able literature. To estimate the contamination rate, we performed a
systematic literature review and meta-analysis. The results of our
study identified a 15.25% contamination rate of reprocessed patient-
ready duodenoscopes.
Multiple outbreaks in the past decades have, to some extent, cre-
ated an awareness of duodenoscope-related infections caused by
Table 1
Study characteristics of included studies.
First author, year Study design Country Hospital Annual
ERCPs
Contaminated
duodenoscopes,
n*
Cultures, n Type of microorganism Reprocessing
method
CFU
threshold
Sampling
setting
Snyder, 2017 [23] Parallel group ran-
domized study
USA Beth Israel Deacon-
ess Medical
Center
1,500 94 516 N/A HLD, dHLD,
HLD/EtO
>0 CFU Non-outbreak
Rauwers, 2018 [24] Descriptive study Netherlands 67 Dutch ERCP
centers1
N/A 33 150 Yeasts,Moraxella spp., Klebsiella pneu-
moniae, Streptococcus salivarius,
Enterobacter cloacae, Moraxella
osloensis, Escherichia coli, Streptococ-
cus mitis,
Klebsiella oxytoca, Neisseria flaves-
cens,
Enterococcus faecium, Rothia spp.,
Enterococcus faecalis, Streptococcus
mutans,
Pseudomonas aeruginosa, Streptococ-
cus oralis,
Staphylococcus aureus, Streptococcus
spp. Bacillus spp., Stenotrophomonas
maltophilia,
Micrococcus luteus, Acinetobacter
spp.,
Staphylococcus epidermidis, Agrobac-
terium radiobacter,
Kocuria spp., Paracoccus yeeii,
Staphylococcus hominis, Achromo-
bacter xylosoxidans,
Staphylococcus warneri, Alternaria
spp.,
Kocuria rhizophila, Pseudomonas
monteilii,
Micrococcus spp., Pseudomonas
putida,
Staphylococcus auricularis, Sphingo-
monas paucimobilis,
Staphylococcus spp. (CNS), Rhizobium
spp. or Sphingobium spp.
HLD  20 CFU Non-outbreak
Rex, 2018 [25] Parallel group ran-
domized study
USA N/A 3,000 59 627 Enterococcus spp. Candida spp., Zygomy-
cete, Micrococcus spp., Staphylococcus
(CNS), Bacillus spp. Corynebacterium
spp.
dHLD N/A Non-outbreak
Heroux, 2017 [26] Parallel group ran-
domized study
USA Beth Israel Deacon-
ess Medical
Center
1,500 19 465 N/A HLD, dHLD, EtO 10 CFU Non-outbreak
Olafsdottir, 2017 [27] Parallel group ran-
domized study
USA Beth Israel Deacon-
ess Medical
Center
1,500 74 390 N/A HLD >0 CFU Non-outbreak
Paula, 2015 [28] Descriptive study Austria Vienna University
Hospital
700 46 412 Unspecified skin bacteria and aerobe
spore-forming bacilli
HLD >100 CFU Non-outbreak
Ross, 2015 [29] Descriptive study USA Virginia Mason
Medical Center
1,500 200 1524 Acinetobacter, Enterococcus, Escheri-
chia coli, Enterobacter, Pseudomonas
aeruginosa, Staphylococcus aureus
(methicillin sensitive), Staphylococ-
cus aureus (methicillin resistant)
HLD N/A Outbreak
(continued on next page)
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Table 1 (Continued)
First author, year Study design Country Hospital Annual
ERCPs
Contaminated
duodenoscopes,
n*
Cultures, n Type of microorganism Reprocessing
method
CFU
threshold
Sampling
setting
Naryzhny, 2015 [30] Descriptive study USA N/A N/A 1 84 Carbapenem-resistant
Enterobacteriaceae
EtO N/A Outbreak
Mark, 2020 [31] Descriptive study USA Children’s Hospital
Colorado
N/A 21 117 Pseudomonas aeruginosa, fungal
organisms, Staphylococcus aureus,
Coagulase negative staphylococcus,
Viridans streptococcus
HLD >10 CFU Non-outbreak
Alfa, 2012 [32] Descriptive study Canada St Boniface General
Hospital
N/A 5 43 gram-positive Bacilli, gram-positive
Cocci
HLD N/A Non-outbreak
Higa, 2018 [33] Parallel group ran-
domized study
USA N/A N/A 33 4307 Staphylococcus aureus, Streptococcus
viridans, Enterococcus, and other
pathogenic enteric gramnegative
organisms.
HLD N/A Outbreak
Azimirad, 2019 [34] Descriptive study Iran N/A N/A 26 68 Pseudomonas aeruginosa, Staphylo-
coccus aureus,
Enterococcus spp., Staphylococcus
epidermidis, Escherichia coli, Entero-
bacter spp.,
Clostridium perfringenes
HLD N/A Non-outbreak
Brandabur, 2016 [35] Parallel group ran-
domized study
USA 21 unspecified
facilities
N/A 201 4032 Coagulase-negative staphylococci,
Bacillus spp, coryneform gram-posi-
tive bacilli, gram-negative glucose-
nonfermenters, enteric gram-nega-
tive bacilli, Pseudomonas aerugi-
nosa, Acinetobacter baumannii,
Staphylococcus aureus, Enterococcus
spp, and Stenotrophomonas
maltophilia
HLD N/A Non-outbreak
Cristina, 2020 [36] Descriptive study Italy N/A 350 93 124 Pseudomonas aeruginosa, Klebsiella
pneumoniae, Acinetobacter bauman-
nii, Klebsiella oxytoca, Stenotropho-
monas maltophilia, Escherichia coli,
Citrobacter freundii, Enterobacter
spp
HLD >10 CFU Non-outbreak
Aumeran, 2010 [37] Descriptive study France N/A N/A 20 253 Klebsiella pneumoniae ESBL CTX-M-
15, Escherichia coli ESBL, Other mul-
tiresistant E. coli, Nonmultiresistant
Enterobacteriaceae, Multiresistant
Pseudomonas aeruginosa, Nonmul-
tiresistant P. aeruginosa, Coagulase
-negative staphylococci, Enterococci,
Anaerobes, yeasts
HLD N/A Outbreak
* Number of positive sampled cultures; colony forming units (CFU); Species (spp.); coagulase - negative staphylococci (CNS).
1 Academic Medical Center (AMC), Amsterdam; Albert Schweitzer Hospital, Dordrecht; Alrijne Hospital, Leiden/Leiderdorp; Amphia Hospital, Breda; Antoni van Leeuwenhoek, Amsterdam; Antonius Zorggroep, Sneek; Beatrix Hospital,
Gorinchem; Bernhoven, Uden; Bravis Hospital, Roosendaal; Canisius Wilhelmina Hospital, Nijmegen; Catharina Hospital Eindhoven, Eindhoven; Deventer Hospital, Deventer; Diakonessenhuis, Utrecht; Elkerliek Hospital, Helmond; Eras-
mus University Medical Center (Erasmus MC), Rotterdam; FlevoHospital, Almere; Groene Hart Hospital, Gouda; Hospital Amstelland, Amstelveen; Hospital De Tjongerschans, Heerenveen; Hospital Gelderse Vallei, Ede; Hospital St. Jansdal,
Harderwijk; IJsselland Hospital, Capelle aan Den IJssel; Ikazia, Rotterdam; Isala Diaconessenhuis, Meppel; Jeroen Bosch Hospital, ’s Hertogenbosch; Laurentius Hospital, Roermond; Leiden University Medical Center (LUMC), Leiden; Maas-
stad Hospital, Rotterdam; Maastricht University Medical Center (MUMC), Maastricht; Martini Hospital, Groningen; Maxima Medical Center, Veldhoven; Meander Medical Center, Amersfoort; Medical Center Alkmaar, Alkmaar; Medical
Center Haaglanden, Den Haag; Medical Center Leeuwarden, Leeuwarden; Medical Center Slotervaart, Amsterdam; Medical Center Zuiderzee, Lelystad; Medisch Spectrum Twente, Enschede; Nij Smellinghe Hospital, Drachten; Ommelander
Hospital Group, Delfzijl; Onze Lieve Vrouwe Gasthuis—Location East/West, Amsterdam; Radboud University Medical Center (Radboudumc), Nijmegen; Reinier de Graaf Hospital, Delft; Rijnstate Hospital, Arnhem; Rode Kruis Hospital, Bev-
erwijk; Slingeland Hospital, Doetinchem; St. Anna Hospital, Eindhoven; St. Antonius Hospital, Nieuwegein; St. Elisabeth Hospital, Tilburg; St. Franciscus Gasthuis, Rotterdam; Tergooi Hospital, Hilversum; Treant Zorggroep, Location
Scheper, Emmen; TweeSteden Hospital, Tilburg/ Waalwijk; University Medical Center Groningen (UMCG), Groningen; University Medical Center Utrecht (UMCU), Utrecht; VieCuri Medical Center, Venlo; VU Medical Center, Amsterdam;
Westfriesgasthuis, Hoorn; Wilhelmina Hospital Assen, Assen; Zaans Medical Center, Zaandam; Ziekenhuisgroep Twente, Almelo; ZorgSaam Hospital, Terneuzen; Zuwe Hofpoort Hospital, Woerden; Zuyderland Medical Center, Heerlen.
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S. Larsen et al. / EClinicalMedicine 25 (2020) 100451 7contaminated duodenoscopes. However, a number of guidelines
continuously underestimate the actual endoscope-related risk of
infection; consequently, the present study aimed to quantify the
contamination rate associated with patient-ready duodenoscopes
[3840]. An endoscope-related infection risk can be difficult to iden-
tify in some cases, due to the baseline risk of infection associated
with ERCP. Approximately 7% of complications are directly related
to ERCP procedures; furthermore, 1% out of these complications is
categorized as severe and often requires intervention, blood transfu-
sion, or hospitalization for more than 10 days [41]. Additionally, the
harm of a duodenoscope-related infection following ERCP might be
difficult to quantify as the procedure itself is often lifesaving. A pre-
vious review by Rubin et al. identified 32 outbreaks between 2000
and 2017, involving almost 400 patients. These authors stated that
the acquisition of precise data related to duodenoscope-related
infections is difficult, since many of the existing studies failed to
perform screening cultures on exposed asymptomatic patients, or
simply failed to include these data. Lastly, Rubin et al. highlighted
that the list of studies they compiled may have underestimated the
morbidity and mortality associated with infections caused by con-
taminated duodenoscopes; this was because their analysis only cap-
tured outbreaks that had been reported [8]. These results indicate
the difficulties in attributing an infection risk to the amount of con-
taminated duodenoscopes.
Because it is difficult to identify the endoscope-related infection
risk caused by contaminated duodenoscopes, the severe consequen-
ces of infections transmitted through a contaminated duodenoscope
are often underestimated. A study published by Humphries et al.,
reported that six out of nine patients with duodenoscope-related car-
bapenem-resistant Enterobacteriaceae (CRE) infections had died one
year after an outbreak had been identified, although only two deaths
were directly related to a CRE infection caused by a contaminated
duodenoscope [42]. The overall mortality associated with ERCP is
estimated to be approximately 0.3% [41,43]. However, mortality rates
can be difficult to link directly to contaminated duodenoscopes; thus,
these data are rarely published, and the actual mortality rate related
to contaminated duodenoscopes may be underestimated [8]. Our
findings suggest a higher than expected contamination rate which
may also indicate a higher-than expected endoscope-related infec-
tion risk, and potentially mortality rate, associated with ERCP [44,45].
Multiple US guidelines, including the Centers for Disease Control and
Prevention (CDC) state that “Even though endoscopes represent a valu-
able diagnostic and therapeutic tool in modern medicine and the inci-
dence of infection associated with their use reportedly is very low (about
1 in 1.8 million procedures), more healthcare-associated outbreaks have
been linked to contaminated endoscopes than to any other medical
device” [38]. The reported incidence of 1 infection in 1.8 million pro-
cedures was originally published in 1993 by Kimmery et al., and may
not necessarily reflect the current status of duodenoscope-related
outbreaks [46]. In addition, since 2010, reusable flexible endoscopes
have featured on every annual list of the ‘Top 10 Technology Hazards’
published by the Environmental Risk Communications, Inc. (ERCI)
Institute, due to issues related to cross-contamination, inadequate
reprocessing, and infection risk [47]. In general, quality problems in
healthcare tend to be overlooked, and that problems are in fact much
larger than we normally assume. This also seems to be the case for
contaminated duodenoscopes, and other endoscopes such as bron-
choscopes, gastroscopes, and colonoscopes [4853].
Despite many gastroenterology societies being aware of the cur-
rent obstacles associated with reprocessing duodenoscopes, the lack
of evidence for this association over the past 25 years suggests that
the issue has been neglected. In October 2019, the official newspaper
of the American Gastroenterological Association (AGA) Institute com-
mented on the risk of acquiring a MDR infection with a duodeno-
scope by saying that “the chance of getting an identified “superbug
infection” with a duodenoscope is very low, currently estimated at 1 per20,000 ERCPs performed in more than 650,000 ERCP procedures each
year in the U.S” [54]. The infection risk announced by the AGA was
the highest infection risk reported this far but was still considered
“very low.” However, once presented, MDR infection is expensive to
treat and is also associated with a reduction in the quality of life [55].
Therefore, it is debatable as to whether 1 MDR infection per 20,000
ERCPs is considered ‘low’ relative to the harm caused by the specific
infected patient. In addition, there is no scientific evidence to support
this risk of infection, thus highlighting the urgent need for further
studies and the acquisition of robust evidence. The AGA statement
was announced shortly after the FDA published a Safety Communica-
tion on the 29th August 2019, which recommended that hospitals
and endoscopy facilities needed to replace fixed endcap duodeno-
scopes with those with newer design features that facilitate or elimi-
nate the need for reprocessing [56].
The rate of contamination observed in our study is consistent with
the rates of contamination for other endoscopes, including broncho-
scopes, gastroscopes, and colonoscopes [5760]. However, our con-
tamination rate is higher than the interim results from the post-
market surveillance study undertaken by the FDA. The interim results
published by the FDA revealed a 9% contamination rate; 5.4% of the
identified organisms were classified as ‘high concern’ due to a high
association with disease caused by bacteria such as E. coli and P. aeru-
ginosa. In November 2019, the FDA released the results of their
‘Human Factors Studies’, which were designed to investigate human
errors associated with manual reprocessing. These studies involved
the three major manufacturers of duodenoscopes (Olympus, Pentax,
and Fujifilm). The results of this study indicated an overall poor
adherence to reprocessing guidelines. This was illustrated by the fact
that 87% of the participants failed to complete the elevator brushing
task that was described in the user manual provided by Olympus.
Furthermore, the user manual of the Fujifilm duodenoscope
described 33 critical manual cleaning tasks; only two of these tasks
were carried out by all of the participants [61]. Furthermore, the
‘Human Factors Studies’ revealed that all cleaning personnel partici-
pating in the study failed to flush the surfaces and inspect the mov-
able parts, and that most participants expressed difficulty adhering
to the reprocessing manual [61]. These new results indicated that the
issues associated with the appropriate reprocessing of duodeno-
scopes is caused by multiple factors, including their complex design,
but also by human factors which can be very difficult to overcome.
The fact that educated cleaning personnel are unable to reprocess the
duodenoscopes in an appropriate manner further increases the risk
of contamination, and thereby, the risk of cross-infection. Due to a
high staff turnover, cleaning personnel tend to lack appropriate train-
ing, and never become highly skilled in reprocessing the endoscopes
in a robust manner. According to The Joint Commission and The Asso-
ciation of Perioperative Registered Nurses (AORN), this practice leads
to high rates of non-compliance with reprocessing guidelines [62,63].
Since 2009, the annual proportion (%) of facilities not complying with
these standards have increased; in 2015, up to 60% of facilities were
non-compliant due to breaches related to HLD and sterilization [62].
Although one contaminated duodenoscope does not necessarily lead
to an infection, it does create a higher risk of infection; such infec-
tions are related to hospital admission, additional healthcare costs,
and expenses for each ERCP patient [64].
Duodenoscopes have a complex design, which makes adequate
reprocessing a challenge. Various mechanical parts inside the duode-
noscope render the device heat-labile. These systems therefore
require robust cleaning routines that do not require heat sterilization
[6567]. The current standard for reprocessing duodenoscopes is
HLD; this standard recommends over 100 cleaning steps, including
precleaning, leak-testing, manual cleaning, and drying [6870]. Pre-
cleaning is an important step as this avoids the formation of biofilm.
Manual cleaning is generally effective but difficult to control in prac-
tice. Furthermore, biofilm is not always successfully removed because
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[71]. Therefore, despite strict adherence to the recommended reproc-
essing guidelines, outbreaks of MDR infections still occur. These out-
breaks have led to the FDA recommending stricter reprocessing
measures as an addition to the current standards provided by the
manufacturers [8,72]. In 2015, The FDA recommended that health-
care facilities repeat HLD, using either EtO gas sterilization or liquid
chemical sterilization. It is also important to check whether the duo-
denoscopes have been cleaned properly by performing microbiolog-
ical cultures [72]. Reusable endoscopes have been linked to far more
outbreaks than any other reusable medical devices in healthcare,
thus suggesting that problems with reprocessing endoscopes, and
especially duodenoscopes, remain a huge challenge, even after the
FDA have recommended stricter and more thorough reprocessing
measures [73]. In our analysis, 12 out of 15 (80.0%) studies report that
HLD was the reprocessing method used prior to sampling and cultur-
ing the duodenoscopes. However, when only looking at the pooled
contamination rate for these studies, the total weighted contamination
rate increased to 16.14% from 15.25%. When only looking at studies
reporting either dHLD or EtO as the reprocessingmethod, the contami-
nation rate decreased to 9.20%. This supports the FDA recommenda-
tions on either using dHLD or EtO, since these reprocessing methods
appear to be more effective compared to single HLD. However, even
after dHLD and EtO sterilizaton duodenoscopes still remain contami-
nated which is a concern. Duodenoscopes become highly contami-
nated because they enter the gastrointestinal tract, and therefore
come into contact with a very high microbial load. This, combined
with the fact that duodenoscopes have a very complex design, render
these systems very difficult to clean properly [73]. Therefore, reproc-
essing strategies are unlikely to solve the problem alone. Redesigning
the duodenoscopes might represent the next step towards eliminating
the cross-infections associated with contaminated reprocessed duode-
noscopes [8]. Findings form our subgroup analyses comparing contam-
ination rates between outbreak-initiated studies and non-outbreak-
initiated studies showed a lower contamination rate amongst out-
break-initiated studies, indicating that duodenoscopes are contami-
nated even in non-outbreak settings.
While the data presented in this study are informative for deci-
sion-making and clinical guidelines, there are several limitations that
should be considered. The main limitation of this review is the low
quality of published evidence. There are several reasons for this
shortfall. First, the included studies were associated with methodo-
logical limitations that were related to their non-randomized design,
mainly because some studies were initiated because of the suspicion
of an outbreak due to contaminated duodenoscopes. Secondly, the
existing literature is inconsistent in regards to methodology, reproc-
essing methods, and especially CFU limits making the results more
difficult to compare. Thirdly, there is the possibility of publication
bias with regards to unpublished studies or studies publishing nega-
tive results. Publication bias represents a substantial limitation in this
study, since we have to assume that several issues with contaminated
duodenoscopes is unreported, especially in Europe where only a very
limited number of studies have been reported. Funnel plots and
Egger’s regression test indicated that significant publication bias
existed amongst the included studies. Lastly, limitations exist in
regards to the two subgroup analyses carried out in this study. The
subgroup analysis investigating the effect of different reprocessing
methods include studies not directly investigating this subject which
increase the risk of confounding factors affecting our findings. Addi-
tionally, both subgroup analyses were based on rather small sample
sizes questioning the validity of the findings. Despite these limita-
tions, the findings of the present study are novel and may help to cre-
ate awareness about the issues concerning cross-contamination
associated with reprocessed patient-ready duodenoscopes.
This study is the first to quantify the contamination rate of
patient-ready duodenoscopes used for ERCP based on currentlyavailable data. Our results showed a 15.25% contamination rate of
reprocessed patient-ready duodenoscopes. Additionally, the analysis
indicates that dHLD and EtO reprocessing methods are superior to
single HLD but still not efficient in regards to cleaning the duodeno-
scopes properly. Lastly, a subgroup analysis indicates that studies
conducted in outbreak settings do not entail a higher contamination
compared to studies initiated in non-outbreak settings. We recom-
mend that more studies will be conducted in the future to address
issues related to contaminated reusable duodenoscopes that may
potentially lead to cross-infections and patient harm following ERCP.
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